[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466513":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":25,"locations":34,"responsibleParty":45,"collaborators":25,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":25,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":25,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":25,"overallStatus":66,"whyStopped":25,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"NVP Healthcare","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NVP-1805","EXPERIMENTAL","orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80\u002F10\u002F20.8mg)",[13],"Drug: NVP-1805",{"label":15,"type":16,"description":17,"interventionNames":18},"NVP-1805-R1 and NVP-1805-R2","ACTIVE_COMPARATOR","orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10\u002F20.8mg)",[19],"Drug: NVP-1805-R1 and NVP-1805-R2",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","NVP-1805 (80\u002F10\u002F20.8mg)",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10\u002F20.8mg)",[15],[30],{"name":31,"affiliation":32,"role":33},"Jaewoo Kim","H Plus Yangji Hospital","PRINCIPAL_INVESTIGATOR",[35],{"facility":36,"status":25,"city":37,"state":25,"zip":25,"country":38,"countryCode":25,"cosmosGeoPoint":39,"geoPoint":44,"contacts":25},"H Plus Yangji Hospita","Seoul","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},{"type":46,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100466513","phase-1-nvp-1805-compared-to-coadministration-of-nvp-1805-r1-with-nvp-1805-r2-in-healthy-adult-volunteers-be-100466513",false,"NCT05354713","NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)","An Clinical Trial to Evaluate the Pharmacokinetics and the Safety of NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult subjects who signed informed consent\n* BMI of \\>18.0 kg\u002Fm2 and \\\u003C30.0 kg\u002Fm2 subject, weight more than 50kg(45 kg or more for woman)\n\nExclusion Criteria:\n\n* Subjects participated in another clinical trial within 6 months prior to administration of the study drug\n* Inadequate subject for the clinical trial by the investigator's decision\n* Subjects participated in another clinical trial within 6 months prior to administration of the study drug",true,"ALL","19 Years",{"count":58,"type":59},58,"ACTUAL","INTERVENTIONAL",[62],"PHASE1","The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2",[65],"Healthy Volunteers","COMPLETED","2023-05-03",{"date":69,"type":59},"2023-05-06",{"date":71,"type":59},"2022-11-05",{"date":73,"type":59},"2023-04-27",{"name":5,"class":6},1]